Skip to main content
Livermore
Livermore
ZHEN

Assembly Biosciences, Inc.

ASMB
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001426800

No open-market purchases or sales by Assembly Biosciences, Inc. insiders were filed in the last 90 days; 92 institutions reported holding it in 13F filings for Q2 2026, worth $514.8M in total; no superinvestor holds it.

Q2 2023 vs. Q1 2023

How the institutions holding Assembly Biosciences, Inc. changed between Q1 2023 and Q2 2023.

All holders in Q2 2023All holders in Q1 2023

13F holders of ASMB: Q1 2023 compared with Q2 2023
MeasureQ1 2023Of which not filed for Q2 2023Q2 2023Change
Holders38132−5
Shares12.1M16.3K10.5M−1.58M (−13.1%)
Value$10.1M$13.7K$12.0M+$1.91M (+18.9%)

1 institution that held it in Q1 2023 haven't filed for Q2 2023 yet. Not filing isn't selling, so the changes leave them out.

New holders (3)

Institutions that held Assembly Biosciences, Inc. at the end of Q2 2023 but not at the end of Q1 2023.

Institutions new to ASMB in Q2 2023
InstitutionSharesValue% of portfolio
Engineers Gate Manager LP10,071$11.6K0.00%
Rhumbline Advisers2,402$2.76K0.00%
Royal Bank of Canada331$00.00%

Sold out (8)

Institutions that held Assembly Biosciences, Inc. at the end of Q1 2023 and filed for Q2 2023 without it.

Institutions that sold out of ASMB in Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
Platinum Investment Management Ltd890,736$748.6K
Dimensional Fund Advisors LP284,185$238.7K
Two Sigma Investments, LP38,303$32.2K
Tower Research Capital LLC (TRC)31,160$26.0K
Jane Street Group, LLC24,305$20.4K
Virtu Financial LLC11,924$10.0K
UBS Group AG10,601$8.90K
Advisory Services Network, LLC1$1

Not filed for Q2 2023 yet (1)

Institutions that held Assembly Biosciences, Inc. at the end of Q1 2023 and haven't filed a 13F for Q2 2023. Not filing isn't selling, so they aren't counted as sold out.

Institutions holding ASMB in Q1 2023 that haven't filed for Q2 2023
InstitutionShares, Q1 2023Value, Q1 2023
ETF Managers Group, LLC16,315$13.7K